Genetic susceptibility to anthracycline-related congestive heart failure in survivors of haematopoietic cell transplantation

British Journal of Haematology

Volumn 163, Issue 2, 2013, Pages 205-213

  Armenian, Saro H ^a   Ding, Yan ^a   Mills, George ^a   Sun, Canlan ^a   Venkataraman, Kalyanasundaram ^b   Wong, Florence Lennie ^a   Neuhausen, Susan L ^a   Senitzer, David ^c   Wang, Shirong ^d   Forman, Stephen J ^c   Bhatia, Smita ^a  

^a Division of Outcomes Research   (United States)

^b City of Hope   (United States)

^c NONE   (United States)

^d Transfusion Medicine   (United States)

Author keywords

Anthracyclines; Congestive heart failure; Genetic susceptibility; Haematopoietic cell transplantation; Late effects

Indexed keywords

ABC TRANSPORTER; ANTHRACYCLINE; BETA 1 ADRENERGIC RECEPTOR; CYCLOPHOSPHAMIDE; ETOPOSIDE; HFE PROTEIN; RAC2 PROTEIN;

ABCC1 GENE; ABCC2 GENE; ADOLESCENT; ADRB1 GENE; ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER RADIOTHERAPY; CANCER SURVIVAL; CANCER SURVIVOR; CHILD; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; ECHOCARDIOGRAPHY; FEMALE; FOLLOW UP; GENE; GENETIC CODE; GENETIC IDENTIFICATION; GENETIC SUSCEPTIBILITY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HFE GENE; HODGKIN DISEASE; HUMAN; HYPERTENSION; LEUKEMIA; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; PRESCHOOL CHILD; PRIORITY JOURNAL; RAC2 GENE; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM;

ANTHRACYCLINES; CONGESTIVE HEART FAILURE; GENETIC SUSCEPTIBILITY; HAEMATOPOIETIC CELL TRANSPLANTATION; LATE EFFECTS;

ADOLESCENT; ADULT; AGED; ALLELES; ANTHRACYCLINES; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HEART FAILURE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA; MALE; MIDDLE AGED; ODDS RATIO; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS; SURVIVORS; YOUNG ADULT;

EID: 84884980889     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12516     Document Type: Article

References (42)

1. Armand, P., Kim, H.T., Rhodes, J., Sainvil, M.M., Cutler, C., Ho, V.T., Koreth, J., Alyea, E.P., Hearsey, D., Neufeld, E.J., Fleming, M.D., Steen, H., Anderson, D., Kwong, R.Y., Soiffer, R.J. & Antin, J.H. (2011) Iron overload in patients with acute leukemia or MDS undergoing myeloablative stem cell transplantation. Biology of Blood and Marrow Transplantation, 17, 852-860.
2. Armenian, S.H. & Bhatia, S. (2008) Cardiovascular disease after hematopoietic cell transplantation-lessons learned. Haematologica, 93, 1132-1136.
3. Armenian, S.H., Sun, C.L., Francisco, L., Steinberger, J., Kurian, S., Wong, F.L., Sharp, J., Sposto, R., Forman, S.J. & Bhatia, S. (2008) Late congestive heart failure after hematopoietic cell transplantation. Journal of Clinical Oncology, 26, 5537-5543.
4. Armenian, S.H., Sun, C.L., Mills, G., Teh, J.B., Francisco, L., Durand, J.B., Wong, F.L., Forman, S.J. & Bhatia, S. (2010) Predictors of late cardiovascular complications in survivors of hematopoietic cell transplantation. Biology of Blood and Marrow Transplantation, 16, 1138-1144.
5. Armenian, S.H., Sun, C.L., Shannon, T., Mills, G., Francisco, L., Venkataraman, K., Wong, F.L., Forman, S.J. & Bhatia, S. (2011) Incidence and predictors of congestive heart failure after autologous hematopoietic cell transplantation. Blood, 118, 6023-6029.
6. Armenian, S.H., Sun, C.L., Vase, T., Ness, K.K., Blum, E., Francisco, L., Venkataraman, K., Samoa, R., Wong, F.L., Forman, S.J. & Bhatia, S. (2012) Cardiovascular risk factors in hematopoietic cell transplantation survivors: role in development of subsequent cardiovascular disease. Blood, 120, 4505-4512.
7. Baker, K.S., Ness, K.K., Steinberger, J., Carter, A., Francisco, L., Burns, L.J., Sklar, C., Forman, S., Weisdorf, D., Gurney, J.G. & Bhatia, S. (2007) Diabetes, hypertension, and cardiovascular events in survivors of hematopoietic cell transplantation: a report from the bone marrow transplantation survivor study. Blood, 109, 1765-1772.
8. Barry, E., Alvarez, J.A., Scully, R.E., Miller, T.L. & Lipshultz, S.E. (2007) Anthracycline-induced cardiotoxicity: course, pathophysiology, prevention and management. Expert Opinion on Pharmacotherapy, 8, 1039-1058.
9. Bhatia, S., Ramsay, N.K., Steinbuch, M., Dusenbery, K.E., Shapiro, R.S., Weisdorf, D.J., Robison, L.L., Miller, J.S. & Neglia, J.P. (1996) Malignant neoplasms following bone marrow transplantation. Blood, 87, 3633-3639.
10. Blanco, J.G., Leisenring, W.M., Gonzalez-Covarrubias, V.M., Kawashima, T.I., Davies, S.M., Relling, M.V., Robison, L.L., Sklar, C.A., Stovall, M. & Bhatia, S. (2008) Genetic polymorphisms in the carbonyl reductase 3 gene CBR3 and the NAD(P)H:quinone oxidoreductase 1 gene NQO1 in patients who developed anthracycline-related congestive heart failure after childhood cancer. Cancer, 112, 2789-2795.
11. Blanco, J.G., Sun, C.L., Landier, W., Chen, L., Esparza-Duran, D., Leisenring, W., Mays, A., Friedman, D.L., Ginsberg, J.P., Hudson, M.M., Neglia, J.P., Oeffinger, K.C., Ritchey, A.K., Villaluna, D., Relling, M.V. & Bhatia, S. (2012) Anthracycline-related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes-a report from the Children's Oncology Group. Journal of Clinical Oncology, 30, 1415-1421.
12. Copelan, E.A. (2006) Hematopoietic stem-cell transplantation. New England Journal of Medicine, 354, 1813-1826.
13. Cui, Y., Konig, J., Buchholz, J.K., Spring, H., Leier, I. & Keppler, D. (1999) Drug resistance and ATP-dependent conjugate transport mediated by the apical multidrug resistance protein, MRP2, permanently expressed in human and canine cells. Molecular Pharmacology, 55, 929-937.
14. van Dalen, E.C., van der Pal, H.J., Caron, H.N. & Kremer, L.C. (2009) Different dosage schedules for reducing cardiotoxicity in cancer patients receiving anthracycline chemotherapy. The Cochrane Database of Systematic Reviews, doi: 10.1002/14651858.CD005008.pub3.
15. Deng, S. & Wojnowski, L. (2007) Genotyping the risk of anthracycline-induced cardiotoxicity. Cardiovascular Toxicology, 7, 129-134.
16. Ding, Y., Sun, C.L., Li, L., Li, M., Francisco, L., Sabado, M., Hahn, B., Gyorffy, J., Noe, J., Larson, G.P., Forman, S.J., Bhatia, R. & Bhatia, S. (2012) Genetic susceptibility to therapy-related leukemia after Hodgkin lymphoma or non-Hodgkin lymphoma: role of drug metabolism, apoptosis and DNA repair. Blood Cancer Journal, 2, e58.
17. Feder, J.N., Gnirke, A., Thomas, W., Tsuchihashi, Z., Ruddy, D.A., Basava, A., Dormishian, F., Domingo, R. Jr, Ellis, M.C., Fullan, A., Hinton, L.M., Jones, N.L., Kimmel, B.E., Kronmal, G.S., Lauer, P., Lee, V.K., Loeb, D.B., Mapa, F.A., McClelland, E., Meyer, N.C., Mintier, G.A., Moeller, N., Moore, T., Morikang, E., Prass, C.E., Quintana, L., Starnes, S.M., Schatzman, R.C., Brunke, K.J., Drayna, D.T., Risch, N.J., Bacon, B.R. & Wolff, R.K. (1996) A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nature Genetics, 13, 399-408.
18. Gonzalez-Covarrubias, V., Zhang, J., Kalabus, J.L., Relling, M.V. & Blanco, J.G. (2009) Pharmacogenetics of human carbonyl reductase 1 (CBR1) in livers from black and white donors. Drug Metabolism and Disposition, 37, 400-407.
19. Hidemura, K., Zhao, Y.L., Ito, K., Nakao, A., Tatsumi, Y., Kanazawa, H., Takagi, K., Ohta, M. & Hasegawa, T. (2003) Shiga-like toxin II impairs hepatobiliary transport of doxorubicin in rats by down-regulation of hepatic P glycoprotein and multidrug resistance-associated protein Mrp2. Antimicrobial Agents and Chemotherapy, 47, 1636-1642.
20. Hunt, S.A., Abraham, W.T., Chin, M.H., Feldman, A.M., Francis, G.S., Ganiats, T.G., Jessup, M., Konstam, M.A., Mancini, D.M., Michl, K., Oates, J.A., Rahko, P.S., Silver, M.A., Stevenson, L.W., Yancy, C.W., Antman, E.M., Smith, S.C. Jr, Adams, C.D., Anderson, J.L., Faxon, D.P., Fuster, V., Halperin, J.L., Hiratzka, L.F., Jacobs, A.K., Nishimura, R., Ornato, J.P., Page, R.L. & Riegel, B. (2005) ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult. Circulation, 112, e154-e235.
21. Konig, J., Nies, A.T., Cui, Y., Leier, I. & Keppler, D. (1999) Conjugate export pumps of the multidrug resistance protein (MRP) family: localization, substrate specificity, and MRP2-mediated drug resistance. Biochimica et Biophysica Acta, 1461, 377-394.
22. Lee, Y.T., Chan, K.K. & Harris, P.A. (1982) Tissue disposition of doxorubicin in experimental animals. Medical and Pediatric Oncology, 10, 259-267.
23. Lipshultz, S.E., Colan, S.D., Gelber, R.D., Perez-Atayde, A.R., Sallan, S.E. & Sanders, S.P. (1991) Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. New England Journal of Medicine, 324, 808-815.
24. Lipshultz, S.E., Lipsitz, S.R., Mone, S.M., Goorin, A.M., Sallan, S.E., Sanders, S.P., Orav, E.J., Gelber, R.D. & Colan, S.D. (1995) Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. New England Journal of Medicine, 332, 1738-1743.
25. Majhail, N.S., Lazarus, H.M. & Burns, L.J. (2008) Iron overload in hematopoietic cell transplantation. Bone Marrow Transplantation, 41, 997-1003.
26. Majhail, N.S., DeFor, T.E., Lazarus, H.M. & Burns, L.J. (2009) Iron-overload after autologous hematopoietic cell transplantation. Leukemia Research, 33, 578-579.
27. Minotti, G., Menna, P., Salvatorelli, E., Cairo, G. & Gianni, L. (2004a) Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacological Reviews, 56, 185-229.
28. Minotti, G., Recalcati, S., Menna, P., Salvatorelli, E., Corna, G. & Cairo, G. (2004b) Doxorubicin cardiotoxicity and the control of iron metabolism: quinone-dependent and independent mechanisms. Methods in Enzymology, 378, 340-361.
29. Miranda, C.J., Makui, H., Soares, R.J., Bilodeau, M., Mui, J., Vali, H., Bertrand, R., Andrews, N.C. & Santos, M.M. (2003) Hfe deficiency increases susceptibility to cardiotoxicity and exacerbates changes in iron metabolism induced by doxorubicin. Blood, 102, 2574-2580.
30. Mordente, A., Minotti, G., Martorana, G.E., Silvestrini, A., Giardina, B. & Meucci, E. (2003) Anthracycline secondary alcohol metabolite formation in human or rabbit heart: biochemical aspects and pharmacologic implications. Biochemical Pharmacology, 66, 989-998.
31. Mulrooney, D.A., Yeazel, M.W., Kawashima, T., Mertens, A.C., Mitby, P., Stovall, M., Donaldson, S.S., Green, D.M., Sklar, C.A., Robison, L.L. & Leisenring, W.M. (2009) Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort. British Medical Journal, 339, b4606.
32. van der Pal, H.J., van Dalen, E.C., van Delden, E., van Dijk, I.W., Kok, W.E., Geskus, R.B., Sieswerda, E., Oldenburger, F., Koning, C.C., van Leeuwen, F.E., Caron, H.N. & Kremer, L.C. (2012) High risk of symptomatic cardiac events in childhood cancer survivors. Journal of Clinical Oncology, 30, 1429-1437.
33. Pritchard, J.K., Stephens, M. & Donnelly, P. (2000) Inference of population structure using multilocus genotype data. Genetics, 155, 945-959.
34. Raddatz, E., Thomas, A.C., Sarre, A. & Benathan, M. (2011) Differential contribution of mitochondria, NADPH oxidases, and glycolysis to region-specific oxidant stress in the anoxic-reoxygenated embryonic heart. American Journal of Physiology. Heart and Circulatory Physiology, 300, H820-H835.
35. Sabatti, C., Service, S. & Freimer, N. (2003) False discovery rate in linkage and association genome screens for complex disorders. Genetics, 164, 829-833.
36. Shankar, S.M., Marina, N., Hudson, M.M., Hodgson, D.C., Adams, M.J., Landier, W., Bhatia, S., Meeske, K., Chen, M.H., Kinahan, K.E., Steinberger, J. & Rosenthal, D. (2008) Monitoring for cardiovascular disease in survivors of childhood cancer: report from the Cardiovascular Disease Task Force of the Children's Oncology Group. Pediatrics, 121, e387-e396.
37. Syrjala, K.L., Langer, S.L., Abrams, J.R., Storer, B.E. & Martin, P.J. (2005) Late effects of hematopoietic cell transplantation among 10-year adult survivors compared with case-matched controls. Journal of Clinical Oncology, 23, 6596-6606.
38. Tichelli, A., Bhatia, S. & Socie, G. (2008) Cardiac and cardiovascular consequences after haematopoietic stem cell transplantation. British Journal of Haematology, 142, 11-26.
39. Vasquez-Vivar, J., Martasek, P., Hogg, N., Masters, B.S., Pritchard, K.A. Jr. & Kalyanaraman, B. (1997) Endothelial nitric oxide synthase-dependent superoxide generation from adriamycin. Biochemistry, 36, 11293-11297.
40. Visscher, H., Ross, C.J., Rassekh, S.R., Barhdadi, A., Dube, M.P., Al-Saloos, H., Sandor, G.S., Caron, H.N., van Dalen, E.C., Kremer, L.C., van der Pal, H.J., Brown, A.M., Rogers, P.C., Phillips, M.S., Rieder, M.J., Carleton, B.C. & Hayden, M.R. (2012) Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children. Journal of Clinical Oncology, 30, 1422-1428.
41. Wingard, J.R., Vogelsang, G.B. & Deeg, H.J. (2002) Stem cell transplantation: supportive care and long-term complications. Hematology/The Education Program of the American Society of Hematology, 2002, 422-444.
42. Wojnowski, L., Kulle, B., Schirmer, M., Schluter, G., Schmidt, A., Rosenberger, A., Vonhof, S., Bickeboller, H., Toliat, M.R., Suk, E.K., Tzvetkov, M., Kruger, A., Seifert, S., Kloess, M., Hahn, H., Loeffler, M., Nurnberg, P., Pfreundschuh, M., Trumper, L., Brockmoller, J. & Hasenfuss, G. (2005) NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity. Circulation, 112, 3754-3762.